| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.22810 |
| P698 | PubMed publication ID | 17763423 |
| P2093 | author name string | Bo Zheng | |
| Iñaki Sanz | |||
| Jennifer Barnard | |||
| Jennifer H Anolik | |||
| R John Looney | |||
| Teresa Owen | |||
| Sunil Kemshetti | |||
| P433 | issue | 9 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| memory B cell | Q1195394 | ||
| P304 | page(s) | 3044-3056 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy | |
| P478 | volume | 56 |
| Q36718239 | A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus |
| Q37577571 | A perspective on B-cell-targeting therapy for SLE. |
| Q37676032 | Advances in diagnosing and managing antibody-mediated rejection |
| Q36307080 | Advances in human B cell phenotypic profiling |
| Q38546315 | An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus |
| Q90289066 | Analysis of the B cell receptor repertoire in six immune-mediated diseases |
| Q36484465 | Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials |
| Q36775342 | Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors |
| Q54980047 | B Cell Modulation Strategies in Autoimmune Diseases: New Concepts. |
| Q41124267 | B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome |
| Q36432935 | B Cells, Antibodies, and More |
| Q47964262 | B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets. |
| Q42221525 | B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. |
| Q49979732 | B cell subset distribution is altered in patients with severe periodontitis. |
| Q37308252 | B cells and immunological tolerance. |
| Q37603296 | B cells as therapeutic targets in SLE. |
| Q37728724 | B cells as under-appreciated mediators of non-auto-immune inflammatory disease |
| Q34605780 | B cells in HIV infection and disease |
| Q37678888 | B cells in the pathogenesis and treatment of rheumatoid arthritis |
| Q36034499 | B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity |
| Q44699204 | B-cell biology and related therapies in systemic lupus erythematosus |
| Q64065093 | B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid |
| Q36049625 | B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels |
| Q51890331 | B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. |
| Q38051302 | B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab |
| Q37542901 | B-cell-directed therapies for autoimmune disease |
| Q41344044 | B-lymphocyte reconstitution after repeated rituximab treatment in a child with steroid-dependent autoimmune hemolytic anemia. |
| Q34245983 | BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus |
| Q47095865 | BAFF- and APRIL-targeted therapy in systemic autoimmune diseases |
| Q36096756 | Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells |
| Q35134860 | Characterization of B cells in muscle-specific kinase antibody myasthenia gravis |
| Q46914275 | Circulating lymphocyte subsets in normal adults are variable and can be clustered into subgroups |
| Q52650355 | Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. |
| Q57155428 | Connective tissue diseases: The conundrum of B cell depletion in SLE |
| Q34979203 | Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys |
| Q49920960 | Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis |
| Q37638196 | Dysregulation of germinal centres in autoimmune disease. |
| Q88744631 | Effect of CD40/CD40L signaling on IL-10-producing regulatory B cells in Chinese children with Henoch-Schönlein purpura nephritis |
| Q33418352 | Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura |
| Q93161825 | Effector and regulatory B cells in immune-mediated kidney disease |
| Q39492463 | Elimination of autoreactive B cells in humanized SCID mouse model of SLE. |
| Q35654669 | Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response |
| Q92538653 | Failure of B Cell Tolerance in CVID |
| Q42096435 | Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis |
| Q33586280 | Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. |
| Q38130933 | Homeostatic T cell proliferation after islet transplantation |
| Q37260869 | Human B cell subsets |
| Q39156034 | Human regulatory B cells in health and disease: therapeutic potential. |
| Q38000487 | IgM memory B cells: a mouse/human paradox. |
| Q35237511 | Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? |
| Q38601426 | Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
| Q102369356 | Impact of deranged B cell subsets distribution in the development of HCV-related cirrhosis and HCC in type two diabetes mellitus |
| Q37436035 | Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets |
| Q36081961 | Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells |
| Q37662690 | Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche |
| Q38676903 | Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal? |
| Q35840704 | Mechanisms of B cell autoimmunity in SLE. |
| Q41963070 | Multiparameter flow cytometry and bioanalytics for B cell profiling in systemic lupus erythematosus |
| Q37535318 | Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. |
| Q36011177 | New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome |
| Q36140819 | Novel Strategy for Phenotypic Characterization of Human B Lymphocytes from Precursors to Effector Cells by Flow Cytometry |
| Q42559263 | Novel human transitional B cell populations revealed by B cell depletion therapy |
| Q37692210 | Off-label use of rituximab in systemic lupus erythematosus: a systematic review |
| Q34555873 | Overexpression of the Cytokine BAFF and Autoimmunity Risk |
| Q35309470 | Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside |
| Q33805974 | Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70 |
| Q26827075 | Polychromatic flow cytometry in evaluating rheumatic disease patients |
| Q89842614 | Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients |
| Q34505630 | Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment |
| Q92405006 | Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome |
| Q34063315 | Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus |
| Q90140091 | Protein-engineered molecules carrying GAD65 epitopes and targeting CD35 selectively down-modulate disease-associated human B lymphocytes |
| Q33829700 | Rationale for B cell targeting in SLE |
| Q39302587 | Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. |
| Q34707354 | Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease |
| Q37729359 | Regulatory B cells in autoimmune diseases |
| Q37790605 | Regulatory B cells in autoimmunity: developments and controversies. |
| Q64904663 | Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin. |
| Q59793796 | Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring |
| Q88239776 | Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review |
| Q33798060 | Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab |
| Q26824451 | Role of B cells in tolerance induction |
| Q35557832 | Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). |
| Q45748588 | Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. |
| Q37851349 | State of the union between metabolism and the immune system in type 2 diabetes. |
| Q58234774 | TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells |
| Q37052724 | Targeted biologic approaches to the treatment of systemic vasculitis |
| Q37814530 | Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? |
| Q38526835 | The expanding family of regulatory B cells. |
| Q27005951 | The outliers become a stampede as immunometabolism reaches a tipping point |
| Q37552019 | Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy |
| Q37963474 | Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies |
| Q27021397 | Treatment options and strategies for antibody mediated rejection after renal transplantation |
| Q36504624 | Treatment targets in systemic lupus erythematosus: biology and clinical perspective |
| Q95789881 | Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice |
| Q34076412 | Two negative randomized controlled trials in lupus: now what? |
| Q24643047 | Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS) |
| Q92240427 | Wuchereria bancrofti-infected individuals harbor distinct IL-10-producing regulatory B and T cell subsets which are affected by anti-filarial treatment |
Search more.